# GPCR catalysts: Structure Therapeutics Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/gpcr/catalysts

> Structure Therapeutics Inc. (GPCR) has 3 upcoming catalysts. The next is the ACCG-2671 topline data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, year only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for GPCR?

Structure Therapeutics Inc. (GPCR) has 3 upcoming catalysts. The next is the ACCG-2671 topline data readout, 1H 2027. Press release filed with the SEC (EX-99): "MAD clinical trial dosing underway, with topline data expected in 1H 2027" [Calendar and source filings](https://sec-api.dev/companies/gpcr/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-124494, https://www.sec.gov/Archives/edgar/data/1888886/000110465926124494/tm2629207d1_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/companies/gpcr/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Structure Therapeutics Inc. |
| Ticker | GPCR (Nasdaq) |
| SEC CIK | 1888886 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/gpcr |

## Cash runway

Cash $1.24B as of 2026-09-30; quarterly burn $101.7M; about 36.6 months of runway at that rate (XBRL company facts, accession 0001104659-26-124503).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2023 | [Aleniglipron trial start](https://sec-api.dev/pdufa/aleniglipron) | GPCR |  | completed | "Furthermore, we initiated the Phase 1b MAD study in January 2023 and completed dosing in otherwise healthy overweight subjects in March 2023." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1888886/000155837024015531/gpcr-20240930x10q.htm)) |
| May 2023 | [Aleniglipron trial start](https://sec-api.dev/pdufa/aleniglipron) | GPCR |  | completed | "In May 2023, we submitted a protocol amendment to the FDA and initiated dosing of the Phase 2a proof-of-concept study in T2DM and obesity." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1888886/000110465926020562/gpcr-20251231x10k.htm)) |
| Jun 2024 | [LTSE-2578 trial start](https://sec-api.dev/pdufa/ltse-2578) | GPCR | idiopathic pulmonary fibrosis | completed | "In June 2024, we initiated a Phase 1 clinical study of LTSE-2578, our oral small molecule antagonist that targets the lysophosphatidic acid 1 receptor ("LPA1R") for the treatment of idiopathic pulmonary fibrosis ("IPF")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1888886/000155837025006989/gpcr-20250331x10q.htm)) |
| Jun 2024 | [Aleniglipron topline data readout](https://sec-api.dev/pdufa/aleniglipron) | GPCR |  | completed, met | "In June 2024, we reported positive topline data from our Phase 2a obesity study, in which aleniglipron demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks (p<0.0001, using least-squares means ("LSM") and analyzed based on the primary efficacy estimand using a mixed model for repeated measures) and demonstrated generally favorable safety and tolerability results following repeated, daily dosing up to 120 mg." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1888886/000110465926020562/gpcr-20251231x10k.htm)) |
| November 13, 2024 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the third quarter ended September 30, 2024, and highlighted recent corporate achievements." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465924117691/tm2428324d1_ex99-1.htm)) |
| 2025 | [LTSE-2578 interim data readout](https://sec-api.dev/pdufa/ltse-2578) | GPCR |  | scheduled | "The randomized, double-blind, placebo-controlled first-in-human clinical study is designed to investigate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of LTSE-2578 in approximately 64 healthy participants and we expect to report initial data in 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1888886/000155837025006989/gpcr-20250331x10q.htm)) |
| February 27, 2025 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465925018275/tm257591d1_ex99-1.htm)) |
| May 8, 2025 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, including obesity, today reported financial results for the first quarter ended March 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465925046149/tm2514150d1_ex99-1.htm)) |
| August 6, 2025 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the second quarter ended June 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465925074712/tm2522431d1_ex99-1.htm)) |
| late 2025 | [Aleniglipron topline data readout](https://sec-api.dev/pdufa/aleniglipron) | GPCR |  | scheduled | "Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and ACCESS II studies anticipated by year-end 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465925046149/tm2514150d1_ex99-1.htm)) |
| Q4 2025 | [ACCG-2671 trial start](https://sec-api.dev/pdufa/accg-2671) | GPCR |  | scheduled | "We expect to initiate Phase 1 clinical study of ACCG-2671 in the fourth quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1888886/000155837025006989/gpcr-20250331x10q.htm)) |
| November 6, 2025 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the third quarter ended September 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465925107740/tm2530323d1_ex99-1.htm)) |
| Dec 2025 | [ACCG-2671 trial start](https://sec-api.dev/pdufa/accg-2671) | GPCR |  | completed | "We are advancing our amylin oral small molecule program and have initiated a Phase 1 clinical trial of our lead candidate, ACCG-2671 in December 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1888886/000110465926092057/gpcr-20260630x10q.htm)) |
| December 8, 2025 | [Aleniglipron topline data readout](https://sec-api.dev/pdufa/aleniglipron) | GPCR |  | completed, positive | "Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced positive topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465925119095/tm2532078d2_ex99-1.htm)) |
| Q1 2026 | [Structure Therapeutics Inc. topline data readout](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | scheduled | "Topline 44-week data from the ACCESS II study with higher doses expected in Q1 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926020494/tm267321d1_ex99-1.htm)) |
| 1H 2026 | [Aleniglipron topline data readout](https://sec-api.dev/pdufa/aleniglipron) | GPCR |  | scheduled | "Data from ACCESS, ACCESS II, body composition, and the ACCESS OLE studies provide a strong foundation to advance aleniglipron into Phase 3 clinical development and the Company expects to report topline results for these studies in the first half of 2026." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1888886/000110465925120013/tm2532078-4_424b5.htm)) |
| February 26, 2026 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926020494/tm267321d1_ex99-1.htm)) |
| March 16, 2026 | [Aleniglipron topline data readout](https://sec-api.dev/pdufa/aleniglipron) | GPCR |  | completed, positive | "Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced positive topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926028023/tm268880d1_ex99-1.htm)) |
| May 7, 2026 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "Reports First Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926057226/tm2613721d1_ex99-1.htm)) |
| 2H 2026 | [ACCG-2671 trial start](https://sec-api.dev/pdufa/accg-2671) | GPCR |  | scheduled | "Additionally, the Company expects to receive Phase 1 study results for ACCG-2671, its dual amylin calcitonin receptor agonist (DACRA) and to initiate a Phase 1 study for its second DACRA development candidate, ACCG-3535, in the second half of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1888886/000110465925119095/tm2532078d2_8k.htm)) |
| Q3 2026 | [Aleniglipron topline data readout](https://sec-api.dev/pdufa/aleniglipron) | GPCR |  | scheduled | "Topline 72-week aleniglipron ACCESS OLE data on track for Q3 2026;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926092017/tm2622407d1_ex99-1.htm)) |
| Aug 2026 | [Aleniglipron trial start](https://sec-api.dev/pdufa/aleniglipron) | GPCR |  | completed | "In August 2026, we initiated the Phase 3 ACCOMPLISH program, which includes two clinical trials evaluating aleniglipron." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1888886/000110465926124503/gpcr-20260930x10q.htm)) |
| August 6, 2026 | [Structure Therapeutics Inc. trial start](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "The Company announced that the first patients have been dosed in the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926092017/tm2622407d1_ex99-1.htm)) |
| August 6, 2026 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the second quarter ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926092017/tm2622407d1_ex99-1.htm)) |
| September 8, 2026 | [ACCG-2671 topline data readout](https://sec-api.dev/pdufa/accg-2671) | GPCR |  | completed, positive | "On September 8, 2026, the Company reported positive topline data for" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/tm2624945d1_8k.htm)) |
| Q4 2026 | [Structure Therapeutics Inc. topline data readout](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | scheduled | "The Company expects to report topline results from the ACCESS OLE and Body Composition studies in Q3 and Q4 2026, respectively." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926057226/tm2613721d1_ex99-1.htm)) |
| Q4 2026 | [Aleniglipron topline data readout](https://sec-api.dev/pdufa/aleniglipron) | GPCR | obesity or overweight and type 2 diabetes mellitus | scheduled | "We anticipate topline results from the body composition trial in the fourth quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1888886/000110465926124503/gpcr-20260930x10q.htm)) |
| Q4 2026 | [ACCG-3535 trial start](https://sec-api.dev/pdufa/accg-3535) | GPCR |  | scheduled | "The Company plans to initiate a Phase 1 clinical trial of its second oral small molecule DACRA candidate, ACCG-3535, in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926124494/tm2629207d1_ex99-1.htm)) |
| November 9, 2026 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the third quarter ended September 30, 2026, and provided a business update across its oral small molecule obesity portfolio." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926124494/tm2629207d1_ex99-1.htm)) |
| 1H 2027 | [ACCG-2671 topline data readout](https://sec-api.dev/pdufa/accg-2671) | GPCR |  | scheduled | "MAD clinical trial dosing underway, with topline data expected in 1H 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926124494/tm2629207d1_ex99-1.htm)) |
| 2H 2028 | [Aleniglipron topline data readout](https://sec-api.dev/pdufa/aleniglipron) | GPCR |  | scheduled | "topline data expected in 2H 2028" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926124494/tm2629207d1_ex99-1.htm)) |
| 2H 2028 | [ACCG-2671 topline data readout](https://sec-api.dev/pdufa/accg-2671) | GPCR |  | scheduled | "The Company expects topline data in the second half of 2028." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/tm2624945d1_8k.htm)) |

## Drugs

- [ACCG-2671](https://sec-api.dev/pdufa/accg-2671): 
- [ACCG-3535](https://sec-api.dev/pdufa/accg-3535): 
- [Aleniglipron](https://sec-api.dev/pdufa/aleniglipron): people living with obesity and/or overweight, obesity or overweight and type 2 diabetes mellitus
- [LTSE-2578](https://sec-api.dev/pdufa/ltse-2578): idiopathic pulmonary fibrosis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/gpcr/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GPCR catalysts: Structure Therapeutics Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/gpcr/catalysts

```bibtex
@misc{secapidev_companies_gpcr_catalysts_20261116,
  title        = {GPCR catalysts: Structure Therapeutics Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/gpcr/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_gpcr_catalysts_20261116","title":"GPCR catalysts: Structure Therapeutics Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/gpcr/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
